AGP Executive Report
Last update: 7 hours agoFDA Oversight: The American Medical Association urged the FDA to apply drug-level scientific standards to botanical products, including cannabis, citing concerns about increasingly potent products and risks such as dependence and overdose. Hemp Rules: Reports warn that federal restrictions expected in December could make many hemp-derived products, including drinks, illegal, putting businesses on notice of a looming market shift. Cannabis Research: A longitudinal study found cannabis flower use among people with premenstrual symptoms rose before menstruation and around ovulation, with higher use on days of worse emotional sensitivity or conflict. Industry Deal: Organigram agreed to acquire Aurora Cannabis in a deal valuing it at $561 million, offering shareholders cash, shares or a mix after a hostile Curaleaf bid was rebuffed. CBD Producers: Hudson Valley small-batch makers are leaning on local farm infrastructure and clear batch and dosage information to distinguish their products.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
